Madrigal: The Easiest Money May Have Been Made [Seeking Alpha]
Madrigal Pharmaceuticals, Inc. (MDGL)
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
madrigalpharma.com
Company Research
Source: Seeking Alpha
MDGL has made three in-licensing deals since July 2025, picking up multiple potential MASH therapeutics, which it plans to develop in combination with resmetirom. A readout from the outcomes study of resmetirom in MASH is set for 2027, although there is not any tighter guidance than that currently. smodj/iStock via Getty Images Madrigal Pharmaceuticals' ( MDGL ) Rezdiffra launch continues to impress, but MDGL isn't resting on its laurels, engaging in business and clinical development to develop next-generation regimes for metabolic dysfunction-associated steatohepatitis (MASH). In August, I rated MDGL a buy, This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relat
Show less
Read more
Impact Snapshot
Event Time:
MDGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDGL alerts
High impacting Madrigal Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MDGL
News
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Madrigal Pharmaceuticals (MDGL) Reports Record 2025 Revenue Driven by Rezdiffra Success [Yahoo! Finance]Yahoo! Finance
- Why Madrigal Pharmaceuticals (MDGL) Is Down 9.7% After Rezdiffra's Near US$1 Billion Debut Year [Yahoo! Finance]Yahoo! Finance
- Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care ConferenceGlobeNewswire
- Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.MarketBeat
MDGL
Earnings
- 2/19/26 - Miss
MDGL
Sec Filings
- 12/12/25 - Form SCHEDULE
- 12/12/25 - Form SCHEDULE
- MDGL's page on the SEC website